Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results